Bohdan Nosyk1, Julio S G Montaner2, Guillaume Colley3, Viviane D Lima3, Keith Chan3, Katherine Heath3, Benita Yip3, Hasina Samji3, Mark Gilbert4, Rolando Barrios5, Réka Gustafson6, Robert S Hogg7. 1. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada; BC Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, BC, Canada. 2. BC Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, BC, Canada; School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada. Electronic address: jmontaner@cfenet.ubc.ca. 3. BC Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, BC, Canada. 4. Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; BC Centre for Disease Control and Prevention, Vancouver, BC, Canada. 5. BC Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, BC, Canada; Vancouver Coastal Health, Vancouver, BC, Canada. 6. Vancouver Coastal Health, Vancouver, BC, Canada. 7. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
Abstract
BACKGROUND: The cascade of HIV care has become a focal point for implementation efforts to maximise the individual and public health benefits of antiretroviral therapy. We aimed to characterise longitudinal changes in engagement with the cascade of HIV care in British Columbia, Canada, from 1996 to 2011. METHODS: We used estimates of provincial HIV prevalence from the Public Health Agency of Canada and linked provincial population-level data to define, longitudinally, the numbers of individuals in each of the eight stages of the cascade of HIV care (HIV infected, diagnosed, linked to HIV care, retained in HIV care, highly active antiretroviral therapy (HAART) indicated, on HAART, adherent to HAART, and virologically suppressed) in British Columbia from 1996 to 2011. We used sensitivity analyses to determine the sensitivity of cascade-stage counts to variations in their definitions. FINDINGS: 13,140 people were classified as diagnosed with HIV/AIDS in British Columbia during the study period. We noted substantial improvements over time in the proportions of individuals at each stage of the cascade of care. Based on prevalence estimates, the proportion of unidentified HIV-positive individuals decreased from 49·0% (estimated range 36·2-57·5%) in 1996 to 29·0% (11·6-40·7%) in 2011, and the proportion of HIV-positive people with viral suppression reached 34·6% (29·0-43·1%) in 2011. INTERPRETATION: Careful mapping of the cascade of care is crucial to understanding what further efforts are needed to maximise the beneficial effects of available interventions and so inform efforts to contain the spread of HIV/AIDS. FUNDING: British Columbia Ministry of Health, US National Institute on Drug Abuse (National Institutes of Health).
BACKGROUND: The cascade of HIV care has become a focal point for implementation efforts to maximise the individual and public health benefits of antiretroviral therapy. We aimed to characterise longitudinal changes in engagement with the cascade of HIV care in British Columbia, Canada, from 1996 to 2011. METHODS: We used estimates of provincial HIV prevalence from the Public Health Agency of Canada and linked provincial population-level data to define, longitudinally, the numbers of individuals in each of the eight stages of the cascade of HIV care (HIV infected, diagnosed, linked to HIV care, retained in HIV care, highly active antiretroviral therapy (HAART) indicated, on HAART, adherent to HAART, and virologically suppressed) in British Columbia from 1996 to 2011. We used sensitivity analyses to determine the sensitivity of cascade-stage counts to variations in their definitions. FINDINGS: 13,140 people were classified as diagnosed with HIV/AIDS in British Columbia during the study period. We noted substantial improvements over time in the proportions of individuals at each stage of the cascade of care. Based on prevalence estimates, the proportion of unidentified HIV-positive individuals decreased from 49·0% (estimated range 36·2-57·5%) in 1996 to 29·0% (11·6-40·7%) in 2011, and the proportion of HIV-positive people with viral suppression reached 34·6% (29·0-43·1%) in 2011. INTERPRETATION: Careful mapping of the cascade of care is crucial to understanding what further efforts are needed to maximise the beneficial effects of available interventions and so inform efforts to contain the spread of HIV/AIDS. FUNDING: British Columbia Ministry of Health, US National Institute on Drug Abuse (National Institutes of Health).
Authors: C C Carpenter; M A Fischl; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Sáag; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding Journal: JAMA Date: 1996-07-10 Impact factor: 56.272
Authors: Moupali Das-Douglas; Elise D Riley; Kathleen Ragland; David Guzman; Richard Clark; Margot B Kushel; David R Bangsberg Journal: AIDS Behav Date: 2008-05-16
Authors: Melanie A Thompson; Judith A Aberg; Pedro Cahn; Julio S G Montaner; Giuliano Rizzardini; Amalio Telenti; José M Gatell; Huldrych F Günthard; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; Peter Reiss; Douglas D Richman; Paul A Volberding; Patrick Yeni; Robert T Schooley Journal: JAMA Date: 2010-07-21 Impact factor: 56.272
Authors: Virginie Demers; Magda Melo; Cynthia Jackevicius; Jafna Cox; Dimitri Kalavrouziotis; Stéphane Rinfret; Karin H Humphries; Helen Johansen; Jack V Tu; Louise Pilote Journal: CMAJ Date: 2008-02-12 Impact factor: 8.262
Authors: Paula Braitstein; Martin W G Brinkhof; François Dabis; Mauro Schechter; Andrew Boulle; Paolo Miotti; Robin Wood; Christian Laurent; Eduardo Sprinz; Catherine Seyler; David R Bangsberg; Eric Balestre; Jonathan A C Sterne; Margaret May; Matthias Egger Journal: Lancet Date: 2006-03-11 Impact factor: 79.321
Authors: Evan Wood; Thomas Kerr; Brandon D L Marshall; Kathy Li; Ruth Zhang; Robert S Hogg; P Richard Harrigan; Julio S G Montaner Journal: BMJ Date: 2009-04-30
Authors: Yu-Hsiang Hsieh; Gabor D Kelen; Oliver Laeyendecker; Chadd K Kraus; Thomas C Quinn; Richard E Rothman Journal: Ann Emerg Med Date: 2015-02-23 Impact factor: 5.721
Authors: Laura Camoni; Mariangela Raimondo; Maria Dorrucci; Vincenza Regine; Maria Cristina Salfa; Barbara Suligoi Journal: AIDS Res Hum Retroviruses Date: 2015-01-06 Impact factor: 2.205
Authors: Jennifer Pankow; Jennifer Willett; Yang Yang; Holly Swan; Richard Dembo; William M Burdon; Yvonne Patterson; Frank S Pearson; Steven Belenko; Linda K Frisman Journal: J Behav Health Serv Res Date: 2018-04 Impact factor: 1.505
Authors: Katelynne Gardner Toren; Susan E Buskin; Julia C Dombrowski; Susan L Cassels; Matthew R Golden Journal: Sex Transm Dis Date: 2016-01 Impact factor: 2.830
Authors: Catherine R Lesko; Lynne A Sampson; William C Miller; Jacquelyn Clymore; Peter A Leone; Heidi Swygard; Kimberly A Powers Journal: J Acquir Immune Defic Syndr Date: 2015-12-15 Impact factor: 3.731